ロード中...
Impact of empagliflozin on diabetic kidney disease
Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule‐glomerular feedback, thereby protect against diabetes‐induced caidio‐renal injuries.[Image: see text]
保存先:
| 出版年: | J Diabetes Investig |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5583951/ https://ncbi.nlm.nih.gov/pubmed/28035769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12615 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|